ANSWER: C

Rationale:

Phase 0 of the ventricular action potential is defined by the rapid opening of voltage-gated sodium channels once the membrane potential reaches threshold (approximately −70 mV). Sodium ions rush into the cell down their electrochemical gradient, producing the steep depolarizing upstroke that carries the membrane potential to approximately +30 mV. The speed and magnitude of this upstroke determine conduction velocity through ventricular myocardium — a principle directly exploited by Class I antiarrhythmic agents, which reduce sodium channel availability and slow conduction.

• Option A: Option A is incorrect: L-type calcium channels open during phase 2, the plateau phase, and sustain it rather than generating the initial upstroke.
• Option B: Option B is incorrect: potassium efflux through delayed rectifier channels drives repolarization during phases 2 and 3 — it does not produce depolarization.
• Option D: Option D is incorrect: closure of inwardly rectifying potassium channels and spontaneous phase 4 depolarization describes the automaticity mechanism of SA and AV nodal pacemaker cells, which lack a fast sodium current; this is not the mechanism of phase 0 in ventricular myocytes.
• Option E: Option E is incorrect: chloride channels play no significant role in generating the ventricular action potential upstroke, and ligand-gated chloride influx is not a recognized contributor to normal cardiac phase 0 depolarization.

ANSWER: A

Rationale:

SA node pacemaker cells lack a significant fast sodium current and instead depolarize slowly during phase 4 through the coordinated action of three inward currents. The hyperpolarization-activated funny current (If), carried primarily by sodium ions through hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, activates at the end of repolarization and provides the initial inward depolarizing drive. As the membrane depolarizes, T-type calcium channels open first, followed by L-type calcium channels, which generate the upstroke of the SA node action potential (phase 0 in nodal cells is calcium-dependent, not sodium-dependent). Simultaneously, potassium conductance through IKr and IKs channels progressively declines, reducing the outward hyperpolarizing current and allowing net membrane depolarization. The rate of phase 4 depolarization determines heart rate and is the target of several antiarrhythmic strategies — beta-blockers reduce If and slow phase 4 slope; ivabradine selectively blocks If.

• Option B: Option B is incorrect: voltage-gated sodium channels are not the primary driver of SA node automaticity; SA node cells fire spontaneously via calcium channels and If, not via fast sodium channels.
• Option C: Option C is incorrect: potassium efflux is an outward, hyperpolarizing current — sustained potassium efflux would oppose depolarization, not drive it.
• Option D: Option D is incorrect: beta-1 adrenergic receptor activation by catecholamines increases the rate of phase 4 depolarization by increasing If and calcium channel activity, but this is a modulatory effect on existing automaticity — it is not the ionic basis of automaticity itself, and beta-1 receptors are G protein-coupled receptors (GPCRs), not ligand-gated ion channels.
• Option E: Option E is incorrect: closure of L-type calcium channels marks the transition from phase 2 to phase 3 repolarization in ventricular myocytes, not the initiation of spontaneous pacemaker depolarization in nodal cells.

ANSWER: E

Rationale:

The SA node is the dominant cardiac pacemaker because its intrinsic firing rate (60–100 beats per minute at rest) is faster than that of any other pacemaker tissue in the heart. AV nodal cells have an intrinsic rate of approximately 40–60 beats per minute, and ventricular Purkinje fibers fire at approximately 20–40 beats per minute. Because the SA node depolarizes first, its impulse reaches subsidiary pacemaker tissues before those cells can complete their own phase 4 depolarization and reach threshold — a phenomenon called overdrive suppression. The subsidiary pacemakers are reset with each SA node impulse and never fire autonomously under normal circumstances. This hierarchy is clinically important: if the SA node fails or is suppressed pharmacologically, escape rhythms arise from AV nodal or ventricular pacemakers at their lower intrinsic rates.

• Option A: Option A is incorrect: the SA node does not actively inhibit lower pacemakers through a direct electrical inhibitory signal; dominance is achieved passively through rate superiority and overdrive suppression, not active inhibition.
• Option B: Option B is incorrect: the AV node, bundle of His, bundle branches, and Purkinje fibers all possess automaticity and can generate spontaneous impulses — they function as subsidiary pacemakers and become apparent as escape rhythms when SA node function fails.
• Option C: Option C is incorrect: SA node cells actually lack a prominent fast sodium current; their phase 0 upstroke is calcium-dependent and relatively slow. Their dominance derives from the steepest phase 4 slope and fastest firing rate, not from fast sodium channel density.
• Option D: Option D is incorrect: the SA node fires at the fastest, not the slowest, intrinsic rate — this is the defining feature of its pacemaker dominance.

ANSWER: B

Rationale:

Class I antiarrhythmic agents are defined by their blockade of voltage-gated sodium channels. By reducing sodium channel availability, these drugs decrease the maximum rate of phase 0 depolarization (Vmax), which slows conduction velocity through atrial and ventricular myocardium and the His-Purkinje system — tissues that depend on fast sodium current for rapid conduction. This is the mechanism shared by all Class I agents, though the three subclasses (Ia, Ib, Ic) differ in the degree of sodium channel block, their effect on action potential duration, and their rate-dependence. Class I agents are sometimes called membrane stabilizers for this reason.

• Option A: Option A is incorrect: blockade of voltage-gated calcium channels is the defining mechanism of Class IV agents (verapamil and diltiazem), not Class I.
• Option C: Option C is incorrect: beta-adrenergic receptor blockade defines Class II agents.
• Option D: Option D is incorrect: blockade of delayed rectifier potassium channels and prolongation of action potential duration defines Class III agents.
• Option E: Option E is incorrect: activation of inwardly rectifying potassium channels (IKACh) describes the mechanism of adenosine and acetylcholine at the AV node — this is not a recognized Vaughan Williams drug class mechanism for antiarrhythmic therapy.

ANSWER: D

Rationale:

Class II antiarrhythmic agents are beta-adrenergic receptor blockers. Their antiarrhythmic action is mediated primarily through competitive antagonism at beta-1 adrenergic receptors on cardiac tissue. By blocking sympathetic stimulation, they slow the rate of phase 4 depolarization in the SA node (reducing heart rate), prolong AV nodal conduction time and refractoriness (useful in rate control for atrial fibrillation and flutter), and reduce automaticity in ectopic pacemaker foci that have been enhanced by catecholamines. These effects make beta-blockers particularly effective in arrhythmias driven by sympathetic excess, such as exercise-induced ventricular tachycardia and arrhythmias occurring in the setting of myocardial ischemia.

• Option A: Option A is incorrect: sodium channel blockade defines Class I agents, not Class II; beta-blockers do not exert their antiarrhythmic effect through direct sodium channel block.
• Option B: Option B is incorrect: potassium channel blockade and action potential duration prolongation define Class III agents.
• Option C: Option C is incorrect: while some beta-blockers have modest calcium channel effects, their primary antiarrhythmic mechanism is not calcium channel blockade — that defines Class IV agents; vascular smooth muscle effects relate to antihypertensive action, not antiarrhythmic action.
• Option E: Option E is incorrect: M2 receptor activation describes the mechanism of direct vagal stimulation or muscarinic agonists such as acetylcholine — not beta-blockers, which act on adrenergic receptors, not muscarinic receptors.

ANSWER: A

Rationale:

Class III antiarrhythmic agents block delayed rectifier potassium channels — primarily IKr (the rapid component, encoded by the human ether-à-go-go-related gene (hERG)) and in some agents IKs (the slow component). Potassium efflux through these channels drives phase 3 repolarization of the cardiac action potential. When these channels are blocked, phase 3 repolarization is delayed, which prolongs action potential duration (APD) and extends the effective refractory period (ERP). A longer ERP means the myocardium remains refractory for a greater portion of the cardiac cycle, making it more difficult for re-entrant circuits to sustain themselves — the primary antiarrhythmic benefit. This mechanism is reflected on the electrocardiogram (ECG) as QT interval prolongation, which is both a pharmacodynamic marker and a potential risk factor for torsades de pointes (TdP), a life-threatening polymorphic ventricular tachycardia. Major Class III agents include amiodarone, sotalol, dofetilide, ibutilide, and dronedarone.

• Option B: Option B is incorrect: sodium channel blockade and slowing of phase 0 defines Class I agents.
• Option C: Option C is incorrect: L-type calcium channel blockade defines Class IV agents; calcium channel blockade shortens rather than prolongs the action potential plateau.
• Option D: Option D is incorrect: If blockade describes the mechanism of ivabradine, a rate-reducing agent that does not belong to a traditional Vaughan Williams class and does not prolong ventricular action potential duration.
• Option E: Option E is incorrect: inwardly rectifying potassium channels (IK1) are responsible for maintaining the resting membrane potential; their blockade is not the mechanism of Class III agents, and complete blockade of repolarization would not constitute a controlled antiarrhythmic effect.

ANSWER: C

Rationale:

Class IV antiarrhythmic agents are the non-dihydropyridine (non-DHP) calcium channel blockers — specifically verapamil and diltiazem. Unlike dihydropyridine calcium channel blockers (amlodipine, nifedipine), which act primarily on vascular smooth muscle, verapamil and diltiazem have significant effects on cardiac conduction tissue. The AV node depends on L-type calcium channels for its phase 0 depolarization (unlike the sodium-dependent fast-response tissue of the ventricles and His-Purkinje system). By blocking these channels, verapamil and diltiazem slow AV nodal conduction velocity and prolong AV nodal refractoriness, which is why they are effective for rate control in atrial fibrillation and flutter, and for terminating AV nodal re-entrant tachycardia. This calcium-dependent conduction in the AV node is also why these agents are absolutely contraindicated in pre-excited atrial fibrillation (Wolff-Parkinson-White (WPW) syndrome with AF) — blocking the AV node in that setting can accelerate conduction over the accessory pathway.

• Option A: Option A is incorrect: beta-adrenergic receptor blockade defines Class II agents, not Class IV; metoprolol and atenolol are Class II.
• Option B: Option B is incorrect: potassium channel blockade and APD prolongation define Class III agents; sotalol and dofetilide are Class III.
• Option D: Option D is incorrect: sodium channel blockade defines Class I agents; flecainide and propafenone are Class Ic agents.
• Option E: Option E is incorrect: adenosine's mechanism (A1 receptor activation and IKACh opening) is pharmacologically relevant and clinically important, but adenosine is not classified as a Class IV agent under the Vaughan Williams system — it is a separate category of AV nodal blocking agent used for acute SVT termination.

ANSWER: E

Rationale:

Class Ib agents — lidocaine and mexiletine — are distinguished from the other Class I subclasses by three features. First, their sodium channel kinetics are rapid: they bind and unbind the sodium channel quickly, making their block highly rate-dependent and most prominent in rapidly firing or ischemic tissue (where sodium channels spend more time in the inactivated state that Ib agents preferentially bind). Second, they shorten rather than prolong action potential duration (APD), primarily by blocking sodium channels during the late plateau phase — this is the opposite of Class Ia agents, which prolong APD. Third, their effect on conduction velocity is modest at normal heart rates, which explains why they produce minimal or no QRS widening at therapeutic doses and why they are essentially inactive against atrial arrhythmias (atrial tissue has a shorter APD baseline, leaving less of the shortened APD window for Ib block to exploit). Lidocaine remains a guideline-supported option for shock-refractory ventricular fibrillation based on the ALPS trial (a landmark randomized trial in out-of-hospital cardiac arrest, published in NEJM 2016).

• Option A: Option A is incorrect: the greatest degree of sodium channel block and most pronounced conduction slowing belong to Class Ic agents (flecainide, propafenone), not Class Ib.
• Option B: Option B is incorrect: Class Ib agents do not significantly block potassium channels; QT prolongation is associated with Class Ia and Class III agents.
• Option C: Option C is incorrect: Class Ib agents are largely ineffective against atrial arrhythmias — the opposite of what this option states; atrial tissue repolarizes quickly, leaving minimal time for Ib-type block to accumulate.
• Option D: Option D is incorrect: Class Ib agents produce less conduction slowing and less QRS widening than Class Ia agents, not more; pronounced QRS widening is the hallmark of Class Ic agents.

ANSWER: B

Rationale:

Amiodarone is pharmacologically unique among antiarrhythmics because it possesses clinically relevant activity across all four Vaughan Williams classes. It blocks voltage-gated sodium channels (Class I effect, contributing to slowed conduction at high heart rates), competitively antagonizes beta-adrenergic receptors (Class II effect, slowing the SA node and AV node), blocks delayed rectifier potassium channels including IKr (Class III effect, the dominant mechanism — prolonging APD and ERP, reflected as QT prolongation on ECG), and blocks L-type calcium channels (Class IV effect, slowing AV nodal conduction). This multi-channel profile makes amiodarone effective across a broader range of arrhythmia types than any single-class agent, but it also contributes to its extensive toxicity profile — thyroid dysfunction, pulmonary toxicity, hepatotoxicity, corneal microdeposits, and peripheral neuropathy — because amiodarone accumulates in multiple tissues over its very long half-life (weeks to months).

• Option A: Option A is incorrect: amiodarone does have some non-selective adrenergic blocking properties, but alpha-adrenergic blockade is not its primary or defining mechanism, and this does not explain its multi-class classification.
• Option C: Option C is incorrect: amiodarone does not act through muscarinic receptors; its effect on heart rate is mediated through beta-adrenergic blockade and calcium channel block at the SA node.
• Option D: Option D is incorrect: while desethylamiodarone (an active metabolite) does contribute to the drug's effects, the multi-class classification reflects the parent drug's own multi-channel actions — not metabolism to separate single-class metabolites.
• Option E: Option E is incorrect: amiodarone's potassium channel block is real and important, but it genuinely blocks multiple channel types rather than merely mimicking multi-class action through high-potency single-channel block.

ANSWER: D

Rationale:

QRS widening is the direct electrocardiographic signature of sodium channel blockade in ventricular and His-Purkinje tissue. The QRS complex represents ventricular depolarization — specifically the time required for the electrical wavefront to traverse the entire ventricular myocardium via the His-Purkinje system and working muscle. When sodium channels are blocked by a Class I agent (particularly Class Ic agents such as flecainide and propafenone, which produce the most pronounced sodium channel block with the slowest unbinding kinetics), phase 0 depolarization is slowed, conduction velocity decreases throughout the ventricles, and it takes longer for the wavefront to complete ventricular activation. This manifests as QRS prolongation on the ECG. QRS widening of more than 25% above baseline is considered a warning sign of sodium channel toxicity, and marked widening (approaching 0.16–0.18 seconds) signals dangerous drug accumulation. This is one reason why Class Ic agents are monitored carefully and why their use in structural heart disease is contraindicated — slowed conduction in diseased tissue creates the substrate for re-entry rather than suppressing it.

• Option A: Option A is incorrect: potassium channel blockade prolongs repolarization and manifests as QT prolongation (not QRS widening); the QRS complex reflects depolarization, not repolarization.
• Option B: Option B is incorrect: hypocalcemia affects myocardial contractility and can prolong the QT interval, but it does not produce QRS widening, and Class Ic agents do not cause hypocalcemia.
• Option C: Option C is incorrect: AV nodal blockade would manifest as PR interval prolongation or higher-degree AV block, not QRS widening; the QRS width reflects intraventricular conduction time, not AV nodal conduction.
• Option E: Option E is incorrect: increased vagal tone slows SA node firing and prolongs the PR interval but does not widen the QRS complex.

ANSWER: A

Rationale:

The QT interval on the ECG measures the time from the onset of ventricular depolarization (QRS) to the end of ventricular repolarization (end of T wave). Class III antiarrhythmic agents block delayed rectifier potassium channels — primarily IKr — which are responsible for driving phase 3 repolarization of the ventricular action potential. When these channels are blocked, phase 3 is delayed, action potential duration (APD) is prolonged, and the QT interval lengthens correspondingly. This is both the intended antiarrhythmic mechanism (a longer effective refractory period makes it harder for re-entrant circuits to sustain themselves) and the primary risk. Excessive QT prolongation — particularly QTc values at or above 500 ms — creates conditions in which EADs can develop during the prolonged repolarization phase. EADs can trigger TdP, a polymorphic ventricular tachycardia that may degenerate into ventricular fibrillation. A QTc of 520 ms in this patient represents a 100 ms increase from baseline and exceeds the threshold at which drug discontinuation or dose reduction is typically required.

• Option B: Option B is incorrect: calcium channel blockade shortens rather than prolongs the action potential plateau, and Class III agents do not have calcium channel blockade as their primary mechanism.
• Option C: Option C is incorrect: Class III agents do not block muscarinic receptors and do not increase sympathetic tone; beta-blockers (Class II) reduce, not increase, sympathetic drive to the heart.
• Option D: Option D is incorrect: sodium channel blockade affects conduction velocity and QRS width — it does not prolong the QT interval through the mechanism described; QT prolongation is a consequence of delayed repolarization via potassium channel block, not sodium channel terminal effects.
• Option E: Option E is incorrect: QT prolongation with Class III agents is a genuine change in ventricular action potential duration, not an artifact; it is directly measurable, reproducible, and causally linked to arrhythmia risk.

ANSWER: C

Rationale:

Class Ia agents distinguish themselves from Class Ib and Class Ic agents not only by the degree of their sodium channel block but by their additional blockade of delayed rectifier potassium channels — particularly IKr. This dual channel block is the pharmacological basis of Class Ia's unique profile. Sodium channel block slows conduction velocity (reducing Vmax and widening the QRS), while potassium channel block prolongs action potential duration (APD), which extends the ERP into a portion of the cardiac cycle that would otherwise be non-refractory. The ERP is the period during which the myocardium cannot be re-excited regardless of stimulus strength — prolonging it by extending APD makes the tissue refractory for longer and reduces the likelihood that a re-entrant circuit can find excitable tissue ahead of its propagating wavefront. On the ECG, this dual effect manifests as both QRS widening (from sodium channel block) and QT prolongation (from potassium channel block and APD extension) — a combination that is characteristic of Class Ia agents and distinguishes them from Class Ib (QRS effect minimal, APD shortened) and Class Ic (QRS widened, APD minimally affected).

• Option A: Option A is incorrect: Class Ia agents do not block beta-adrenergic receptors; beta-blockade defines Class II agents.
• Option B: Option B is incorrect: Class Ia agents do not stimulate the vagus nerve; some (notably quinidine) actually have antimuscarinic properties that can increase heart rate and AV nodal conduction — the opposite of vagal stimulation.
• Option D: Option D is incorrect: intracellular calcium chelation is not the mechanism of Class Ia agents; the APD prolongation is due to potassium channel block, not calcium manipulation.
• Option E: Option E is incorrect: adenylyl cyclase activation and cAMP-mediated effects describe the downstream pathway of beta-adrenergic receptor stimulation, not the mechanism of Class Ia antiarrhythmics.

ANSWER: E

Rationale:

Use-dependence (also called frequency-dependence or rate-dependence) is defined by the accumulation of sodium channel block at higher firing rates. Class I agents bind to sodium channels in their open or inactivated state and then dissociate during the interval between action potentials (the diastolic interval). At slower heart rates, the diastolic interval is long enough for substantial drug dissociation, so channel block is relatively modest. At faster heart rates, the diastolic interval shortens, less drug dissociates between beats, and the cumulative fraction of blocked channels increases. This means that Class I agents exert greater suppression of conduction in rapidly firing tissue — which is precisely the tissue generating or sustaining a tachyarrhythmia — while having relatively less effect on normally paced tissue at physiological rates. Use-dependence is also the reason Class Ic agents can paradoxically accelerate ventricular rate during atrial flutter: they slow atrial rate enough to allow 1:1 AV conduction at a faster ventricular rate than the prior 2:1 or 3:1 flutter pattern. In the context of structural heart disease (where diseased tissue fires aberrantly), use-dependence means the drug's block is most concentrated precisely where re-entrant circuits are most active — but this also means that QRS widening can become extreme and proarrhythmic at faster rates, which is the basis of the CAST trial finding.

• Option A: Option A is incorrect: use-dependence has nothing to do with requiring combination therapy; it is a pharmacodynamic property of the drug-channel interaction.
• Option B: Option B is incorrect: tissue accumulation and duration-dependent toxicity describe pharmacokinetic properties of some agents (notably amiodarone) but do not define use-dependence.
• Option C: Option C is incorrect: while Class I agents may preferentially affect diseased tissue for multiple reasons, use-dependence specifically refers to rate-dependent channel block kinetics, not to differential sodium channel expression levels.
• Option D: Option D is incorrect: Class I agents are dosed using standard pharmacokinetic principles — plasma drug concentrations, half-lives, and renal/hepatic function — not arrhythmia episode frequency.

ANSWER: B

Rationale:

Re-entry requires two essential conditions. First, there must be unidirectional block in one limb of the circuit — that is, the electrical impulse can travel in only one direction through that pathway (for example, it is blocked in the antegrade direction but can be conducted retrograde). This creates a loop rather than a dead end. Second, conduction through the alternate limb must be slow enough — or the blocked limb must recover excitability fast enough — that by the time the wavefront travels around the loop and returns to the entry point of the blocked pathway, that pathway has recovered and is now excitable in the retrograde direction. This allows the impulse to re-enter and re-excite tissue it has already passed through, establishing a self-sustaining circus movement. The antiarrhythmic strategies that interrupt re-entry act on one or both of these conditions: agents that speed conduction can convert unidirectional block to bidirectional block (extinguishing the circuit), while agents that prolong refractoriness can ensure that the blocked pathway has not recovered by the time the wavefront returns (making re-entry geometrically impossible).

• Option A: Option A is incorrect: the scenario described — increased automaticity with failed overdrive suppression — describes enhanced automaticity as the arrhythmia mechanism, not re-entry. Automaticity-driven arrhythmias and re-entrant arrhythmias are distinct and respond differently to antiarrhythmic strategies.
• Option C: Option C is incorrect: triggered activity from early afterdepolarizations (EADs) and impaired sarcoplasmic reticulum (SR) calcium reuptake describes a distinct mechanism (triggered automaticity), not re-entry; this mechanism underlies TdP and some digoxin-toxic arrhythmias but does not require the geometric circuit that defines re-entry.
• Option D: Option D is incorrect: complete bidirectional block in both limbs would extinguish conduction entirely — no arrhythmia can be sustained if no pathway conducts; re-entry specifically requires that at least one limb conducts.
• Option E: Option E is incorrect: accelerated phase 4 depolarization and shortened ERP may increase arrhythmia susceptibility but describe conditions that promote automaticity and reduce protection against re-entry — they do not define the mechanistic requirements for re-entry itself.

ANSWER: D

Rationale:

EADs and DADs represent two distinct forms of triggered activity that differ in timing, ionic mechanism, and clinical context. EADs occur during the action potential itself — during phase 2 or phase 3 — before repolarization is complete. They arise when the action potential is abnormally prolonged, which allows L-type calcium channels or late sodium channels to reactivate during the extended plateau, generating a depolarizing oscillation that may reach threshold and trigger a premature beat. Conditions that prolong the action potential — Class III antiarrhythmics, hypokalemia, hypomagnesemia, bradycardia, congenital long QT syndrome — predispose to EADs. TdP is the clinical arrhythmia most directly linked to EAD-triggered activity. DADs, by contrast, occur after the action potential has fully repolarized, during phase 4. They are driven by intracellular calcium overload: excess calcium in the sarcoplasmic reticulum (SR) triggers spontaneous calcium release via ryanodine receptors (RyR2), which activates the sodium-calcium exchanger (NCX) in a depolarizing mode (3 Na+ in, 1 Ca2+ out), generating a transient inward current that can reach threshold. Digoxin toxicity (which raises intracellular calcium by inhibiting the Na+/K+-ATPase) and catecholamine excess (which increases SR calcium loading) are classic DAD triggers.

• Option A: Option A is incorrect: EADs do not arise in phase 4 from sodium channel reactivation, and DADs are caused by calcium overload (not depletion) driving NCX in the depolarizing direction.
• Option B: Option B is incorrect: both EADs and DADs can reach threshold and trigger propagated action potentials — the distinction is not amplitude but timing and mechanism.
• Option C: Option C is incorrect: EADs and DADs are not determined by autonomic input patterns; they are defined by their phase of occurrence and ionic mechanism, independent of whether the trigger is vagal or adrenergic.
• Option E: Option E is incorrect: EADs do not occur during phase 0, which is the upstroke driven by fast sodium current; phase 0 abnormalities affect conduction velocity, not afterdepolarization generation.

ANSWER: A

Rationale:

The CAST trial is one of the most consequential studies in the history of antiarrhythmic pharmacology. It enrolled post-myocardial infarction patients with asymptomatic or mildly symptomatic ventricular arrhythmias and randomized them to flecainide, encainide, or placebo. Both active agents effectively suppressed PVCs — achieving the surrogate endpoint — but both increased total mortality and arrhythmic death compared with placebo. The trial was stopped early because of this finding. The mechanistic explanation centers on use-dependence in diseased myocardium: ischemic and fibrotic tissue conducts slowly and heterogeneously, and Class Ic agents — which produce the most potent, slowest-unbinding sodium channel block — worsen this conduction slowing in a rate-dependent manner, creating new re-entrant substrates rather than suppressing existing ones. CAST established two principles that govern antiarrhythmic prescribing to this day: first, that suppression of an arrhythmia surrogate does not equate to clinical benefit or survival; second, that Class Ic agents are contraindicated in structural heart disease regardless of current ejection fraction — the post-MI substrate itself is the contraindication, not the current LVEF.

• Option B: Option B is incorrect: Class Ic agents do not block SA node calcium channels and do not cause bradycardia through this mechanism; their primary effect is sodium channel block in fast-response tissue.
• Option C: Option C is incorrect: Class Ic agents produce minimal QT prolongation (they widen QRS but do not significantly prolong APD); the excess mortality in CAST was due to proarrhythmic ventricular tachycardia from worsened conduction in diseased myocardium, not from TdP.
• Option D: Option D is incorrect: the contraindication is not LVEF-dependent — it applies to any patient with structural heart disease, including post-MI patients regardless of current ejection fraction; there is no preserved-EF exemption for Class Ic use post-MI.
• Option E: Option E is incorrect: while flecainide is a CYP2D6 substrate (not a potent inhibitor), drug interaction is not the mechanism of CAST mortality; the excess deaths were arrhythmic deaths from proarrhythmic conduction effects, not from pharmacokinetic interactions with other agents.

ANSWER: C

Rationale:

Adenosine acts through A1 purinergic receptors, which are expressed at high density on AV nodal cells. A1 receptors are coupled to inhibitory Gi proteins. When adenosine binds, Gi activation releases the Gβγ subunit, which directly opens IKACh channels (the acetylcholine-sensitive inwardly rectifying potassium channel). The resulting potassium efflux hyperpolarizes the AV nodal cell membrane, making it less excitable and slowing or transiently blocking conduction through the node. This brief period of AV block interrupts the re-entrant circuit that depends on continuous AV nodal conduction — most commonly AV nodal re-entrant tachycardia (AVNRT) or AV re-entrant tachycardia (AVRT) using an accessory pathway. Because adenosine has an extremely short half-life (less than 10 seconds, rapidly inactivated by adenosine deaminase and cellular uptake), its AV block is transient and sinus rhythm resumes within seconds. Adenosine is also diagnostically useful: in atrial flutter or atrial tachycardia, it slows the ventricular rate temporarily and unmasks the underlying atrial activity without terminating the arrhythmia, clarifying the diagnosis.

• Option A: Option A is incorrect: adenosine does not block voltage-gated sodium channels; its mechanism is receptor-mediated via Gi and IKACh, not direct ion channel block.
• Option B: Option B is incorrect: adenosine does not block beta-adrenergic receptors; its receptor target is the A1 adenosine receptor, a GPCR distinct from adrenergic receptors.
• Option D: Option D is incorrect: adenosine does not block potassium channels — it opens them; furthermore, opening IKACh (not blocking it) is responsible for hyperpolarization and AV block.
• Option E: Option E is incorrect: adenosine acts directly on AV nodal cells through A1 receptors — it does not work through carotid sinus reflex arcs or vagal efferent pathways, though its downstream ionic effect (IKACh opening) is similar to that of vagal acetylcholine at the AV node.

ANSWER: E

Rationale:

In pre-excited atrial fibrillation (AF conducted over an accessory pathway in WPW syndrome), the primary danger is the extremely rapid ventricular rate that results from unfiltered conduction of atrial impulses directly to the ventricles via the accessory pathway — which, unlike the AV node, lacks the decremental conduction properties that limit the ventricular rate in normal AF. AV nodal blocking agents — including verapamil, diltiazem, beta-blockers, digoxin, and adenosine — are contraindicated in this setting. By slowing or blocking conduction through the AV node, these agents paradoxically remove the only competing pathway that was partially absorbing atrial impulses, leaving the accessory pathway as the sole route and potentially accelerating the ventricular rate dramatically. At rates above 250 beats per minute, the risk of degeneration to ventricular fibrillation is substantial. Verapamil additionally may cause peripheral vasodilation and hypotension, further destabilizing a patient who is already hemodynamically stressed. The appropriate treatment for stable pre-excited AF is intravenous procainamide (Class Ia, slows accessory pathway conduction) or ibutilide; for unstable patients, immediate electrical cardioversion is the treatment of choice. Options A, B, C, and D each describe agents or interventions that are appropriate or acceptable in pre-excited AF.

• Option A: Option A is not incorrect: procainamide slows accessory pathway conduction and is guideline-supported for stable pre-excited AF.
• Option B: Option B is not incorrect: ibutilide prolongs refractoriness in the accessory pathway and AV node and has been used for rhythm conversion in pre-excited AF.
• Option C: Option C is not incorrect: electrical cardioversion is the first-line treatment for hemodynamically unstable pre-excited AF and is always appropriate.
• Option D: Option D requires clarification: flecainide is sometimes used for pre-excited AF in patients without structural heart disease, though it is used less commonly than procainamide in the acute setting; its use here is not the dangerous choice. Only Option E — verapamil — represents a contraindicated agent whose administration in pre-excited AF carries a documented risk of precipitating ventricular fibrillation.

ANSWER: B

Rationale:

Sotalol is unique among commonly used antiarrhythmics in being eliminated almost entirely unchanged by renal excretion — hepatic metabolism plays a negligible role. In patients with renal impairment, sotalol clearance falls proportionally to the decline in GFR, causing drug accumulation and elevated plasma concentrations. The consequences are primarily electrophysiological: elevated sotalol levels produce greater IKr blockade, more pronounced QTc prolongation, and a substantially increased risk of TdP. The FDA label for sotalol specifies that it is contraindicated when CrCl falls below 40 mL/min for the atrial fibrillation indication (and below 40 mL/min for the ventricular arrhythmia indication as well). This patient's CrCl of 32 mL/min falls below this threshold, making sotalol contraindicated. For patients who do require sotalol at borderline renal function, the label mandates dose adjustment by CrCl tier and in-hospital initiation with continuous QTc monitoring — but at 32 mL/min, adjustment alone is insufficient.

• Option A: Option A is incorrect: sotalol is not hepatically metabolized and does not induce CYP3A4; its clearance is renal, not hepatic.
• Option C: Option C is incorrect: both the Class II and Class III activities of sotalol are pharmacologically intact in renal impairment — the problem is accumulation of both activities, not selective loss of one.
• Option D: Option D is incorrect: sotalol does not cause hyperkalemia through potassium channel blocking; channel block prevents potassium from leaving the cell during repolarization but does not raise serum potassium; the QT risk from sotalol accumulation is from the drug effect on the channel, not from electrolyte shifts.
• Option E: Option E is incorrect: sotalol has no aldosterone-antagonist properties; this mechanism describes spironolactone or eplerenone, not sotalol.

ANSWER: D

Rationale:

The AFFIRM trial, published in 2002, randomized over 4,000 patients with AF to rate control versus rhythm control and found no significant difference in overall mortality between the two strategies. This was a landmark finding that shifted clinical practice toward accepting rate control as a reasonable primary strategy for many patients, particularly older asymptomatic patients in whom antiarrhythmic drug toxicity represents a meaningful risk. However, the rate-versus-rhythm debate was substantially reframed by the EAST-AFNET 4 trial (published in NEJM 2020), which randomized patients with early AF (diagnosed within the prior 12 months) to early rhythm control versus usual care and demonstrated a significant reduction in a composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome in the early rhythm control group — without an increase in adverse events. EAST-AFNET 4 established that the timing of rhythm control initiation matters: early intervention in appropriately selected patients produces outcomes superior to the delayed or reactive rhythm control strategies tested in AFFIRM. For this asymptomatic patient with adequate rate control already achieved, either strategy remains acceptable, but the evidence now supports discussing early rhythm control as an option that may reduce long-term cardiovascular events. Anticoagulation decisions are made independently of rate or rhythm strategy based on stroke risk scores — rhythm control does not justify discontinuing anticoagulation.

• Option A: Option A is incorrect: restoring sinus rhythm does not allow anticoagulation to be discontinued; stroke risk is determined by the CHA2DS2-VASc score (a validated stroke risk stratification tool in AF, incorporating Congestive heart failure, Hypertension, Age, Diabetes, Stroke history, Vascular disease, and Sex category), not by rhythm status, and anticoagulation is generally continued in patients at elevated stroke risk regardless of rhythm.
• Option B: Option B is incorrect: age alone does not contraindicate rhythm control; many older patients benefit from it, and the decision is individualized.
• Option C: Option C is incorrect: rhythm control does not uniformly worsen quality of life — many patients report symptom improvement with restoration of sinus rhythm, and quality of life is frequently the primary motivation for pursuing rhythm control.
• Option E: Option E is incorrect: while tachycardia-mediated cardiomyopathy is a real entity, rate control (by controlling ventricular rate) can also reverse it; rhythm control is not universally superior for all patients on this basis.

ANSWER: A

Rationale:

Flecainide and other Class Ic agents can convert AF to atrial flutter — a recognized transitional rhythm during pharmacological rhythm control. The proarrhythmic danger arises from a combination of two flecainide effects. First, through use-dependent sodium channel block in atrial tissue, flecainide slows the atrial flutter cycle length — the flutter rate decreases from the typical 300 beats per minute to perhaps 200–240 beats per minute. Second, flecainide's AV nodal effects are relatively modest, and the slower flutter rate may fall within the range of 1:1 AV conduction (whereas the original faster flutter was conducted 2:1 or 3:1, producing a manageable ventricular rate of 150 or 100 beats per minute). When 1:1 conduction occurs at a flutter rate of 200–240 beats per minute, the ventricular rate is 200–240 beats per minute — faster than before drug treatment — and the wide QRS (from rate-dependent sodium channel block widening conduction) makes the rhythm look like ventricular tachycardia. This is why Class Ic agents used for AF rhythm control are typically co-prescribed with an AV nodal blocking agent (beta-blocker or non-DHP CCB) to prevent 1:1 conduction if flutter develops.

• Option B: Option B is incorrect: sodium channel block does not activate latent accessory pathways; accessory pathway conduction is independent of normal sodium channel function in working myocardium.
• Option C: Option C is incorrect: proarrhythmia with Class Ic agents can occur in structurally normal hearts, as illustrated by this clinical scenario; the CAST contraindication applies specifically to structural heart disease, but the flutter/1:1 mechanism is not restricted to diseased hearts.
• Option D: Option D is incorrect: flecainide does not cause hypokalemia and does not significantly prolong the QT interval; Class Ic agents widen the QRS but not the QT, and TdP is not the expected proarrhythmic mechanism for this drug class.
• Option E: Option E is incorrect: Class Ic agents widen the QRS (increase conduction time) rather than shorten it; they slow, not accelerate, conduction, and the proarrhythmic mechanism is not QRS shortening.

ANSWER: C

Rationale:

Dronedarone carries two categorical contraindications that directly apply to this patient. First, permanent AF: dronedarone is contraindicated in patients with permanent AF — defined as AF in which rhythm restoration is no longer being pursued. The PALLAS trial (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy) was stopped early due to a significant increase in cardiovascular events including stroke, hospitalization for heart failure, and cardiovascular death in patients with permanent AF randomized to dronedarone. This finding reflects that dronedarone's benefit in AF is tied to maintaining sinus rhythm — in permanent AF, there is no sinus rhythm to maintain, and the drug's harms emerge without the offsetting benefit. Second, HFrEF: dronedarone is contraindicated in patients with heart failure with reduced ejection fraction. The ANDROMEDA trial (Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease) enrolled patients with symptomatic HF and LVEF below 35% and was stopped early due to excess mortality in the dronedarone arm, attributed primarily to worsening heart failure. This patient has both contraindications — permanent AF and LVEF 35% — making dronedarone inappropriate.

• Option A: Option A is incorrect: renal excretion is not the primary concern with dronedarone and CrCl is not the basis of its major contraindications; the permanent AF and HFrEF contraindications are the clinically decisive issues.
• Option B: Option B is incorrect: while dronedarone does interact with warfarin through CYP2C9 inhibition and requires INR monitoring (or dose adjustment of warfarin), this is a drug interaction requiring management — not an absolute contraindication to the combination; and it does not supersede the categorical contraindications that apply to this patient.
• Option D: Option D is incorrect: dronedarone lacks the iodine moiety of amiodarone and has a substantially lower risk of thyroid and pulmonary toxicity; it does not require the same baseline workup as amiodarone, and these are not its primary contraindications.
• Option E: Option E is incorrect: dronedarone is not specifically contraindicated in WPW, and it is absolutely contraindicated in HFrEF — the claim that it is safe in reduced ejection fraction with rate control is directly contradicted by the ANDROMEDA trial.